Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk

Dow Jones

08/21

0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

August 21, 2025 05:41 ET (09:41 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2561463251"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561463251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561463251?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561463251","market":"fut","top_or_hot":-1,"title":"Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 21, 2025 05:41 ET (09:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuxi Biologics Gains New Bull on Growing Order Backlog, Strong Momentum -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-21 17:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 21, 2025 05:41 ET (09:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823426480.USD","symbol_name":"法巴中国股票经典Dis","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2561463251","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561463251","pubTimestamp":1755769260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1610":"ETF&股票定投概念","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1141":"生命科学工具和服务","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","02269":"药明生物","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK1589":"北水核心资产","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1576":"医药外包概念"},"translate_title":"药明生物积压订单增长势头强劲，获得新牛市——市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9},"content_text":"0941 GMT - Wuxi Biologics gains a new bull in CGS International's Lily Wang, who likes its strong momentum. Subsidiary Wuxi XDC, which specializes in antibody-drug conjugate, could contribute a higher order volume share going forward, given its new facility starting up in 2026, she says in a note. Commercial projects should drive demand for antibody-drug conjugate manufacturing capacity, she adds. She notes other segments also show healthy growth, as Wuxi Biologics' 1H new order backlog excluding XDC was much higher than for 2H 2024. Wang raises her 2025-2027 revenue and profit forecasts for Wuxi Biologics to reflect XDC's top-line growth and overall higher margin estimates, respectively. CGS International raises its rating to add from hold and revises up its target to HK$35.79 from HK$25.06. Shares closed at HK$31.32. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2025 05:41 ET (09:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}